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The chemical distribution and mechanical effects of drug compounds in loaded electrospun 21 
scaffolds, a potential material for hernia repair mesh, were characterised and the efficacy of 22 
the material was evaluated. Polycaprolactone electrospun fibres were loaded with either the 23 
antibacterial agent, irgasan, or the broad-spectrum antibiotic, levofloxacin. The samples were 24 
subsequently characterised by rheological studies, scanning electron microscopy (SEM), 25 
atomic force microscopy (AFM), contact angle goniometry (CAG), in vitro drug release 26 
studies, antibacterial studies and time-of-flight secondary ion mass spectrometry (ToF-27 
SIMS).  Increased linear viscoelastic regions observed in the rheometry studies suggest that 28 
both irgasan and levofloxacin alter the internal structure of the native polymeric matrix. In 29 
vitro drug release studies from the loaded polymeric matrix showed significant differences in 30 
release rates for the two drug compounds under investigation. Irgasan showed sustained 31 
release, most likely driven by molecular diffusion through the scaffold.  Conversely, 32 
levofloxacin exhibited a burst release profile indicative of phase separation at the edge of the 33 
fibres. Two scaffold types successfully inhibited bacterial growth when tested with strains of 34 
E. coli and S. aureus.  Electrospinning drug-loaded polyester fibres is an alternative, feasible 35 
and effective method for fabricating non-woven fibrous meshes for controlled release in 36 
hernia repair. 37 
 38 
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1. Introduction 43 
Hernia repair, one of the most common general surgeries performed, is complicated by 44 
bacterial infections and implant rejection [1]. Commercially available mesh devices currently 45 
employed in hernia repairs contain brained or knitted fibres. The mechanical properties of the 46 
mesh and the biocompatibility of the material are critical to the healing process. Tissue 47 
incorporation, a key factor in the success of the graft device is dependent on the material 48 
type, density, compliance and electrical properties of the mesh [2]. Graft failure motivates 49 
research into new fabrication methods for incorporating biomaterials and drug encapsulation 50 
in novel mesh matrices, such as hot-melt extrusion [3], electrospinning [4], 3D printing [5] 51 
and high-speed rotary spinning [6]. 52 
Electrospinning is the most popular and preferred technique for nanofiber fabrication due to 53 
its simplicity, cost-effectiveness, flexibility, and ability to spin a broad range of polymers [7]. 54 
The method allows for the simple and direct functionalization of fibres with drug compounds 55 
and is compatible with solvents such as chloroform and dimethyl sulfoxide. In addition, the 56 
process of electrospinning with the use of solvents such as chloroform, dimethyl sulfoxide 57 
etc., allows functionalisation of the scaffolds through the inclusion of drugs in the polymer-58 
solvent solution without the need for a complicated preparation process [8]. Electrospinning 59 
has previously been applied to the  fabrication of  triclosan/cyclodextrin inclusion complexes 60 
[9], the construction of scaffolds with perlecan domain IV peptides [10], manufacture of 61 
biocatalytic protein membranes [11], and encapsulation of levofloxacin in mesoporous silica 62 
nanoparticles [12]. Given the broad applications of electrospinning, there has been previous 63 
research specifically focused on the development of electrospun polymeric materials for 64 
hernia repair mesh devices. Electrospinning produces scaffolds containing micro-fibres and 65 
this is an advantageous feature not observed in braided mesh commercial devices ± these 66 
microfibers also introduce mechanical anisotropy and provide topographic features to guide 67 




cell alignment [13].  However, electrospun fibres typically incorporate the use of organic 68 
solvents and for applications such as hernia repair or tissue engineering, the toxicity of 69 
organic solvents used could be highly critical ± avoiding organic solvents is of outmost 70 
importance for applications in medicine and pharmacy [14], [15]. 71 
The purpose of this study is to examine the physicochemical properties, bacteria response, 72 
and drug loading of electrospun scaffolds. The polymer chosen for this study is 73 
polycaprolactone (PCL); a biodegradable polyester commonly used in biomedical 74 
applications for controlled release and targeted drug delivery [16]. PCL, a biodegradable 75 
aliphatic polyester [17], is an obvious candidate for drug delivery systems due to its high 76 
biocompatibility and ease of degradation in the human body [18].  Drug loading of structures 77 
that mechanically resemble interfacial tissue and which allows short or long-term release of 78 
suitable bioactives may be utilisable in hernia-repair meshes. PCL was chosen in this research 79 
as it has a high permeability to a variety of drug molecules (e.g. gentamycin, chitosan) and 80 
low toxicity [19].  The matrix was loaded and electrospun with two drugs, irgasan (an 81 
antibacterial agent used commonly in soaps, detergents and surgical cleaning agents) or 82 
levofloxacin (a broad-spectrum antibiotic used commonly to treat gastrointestinal infections). 83 
The mechanical characteristics, morphology, surface hydrophobicity, drug efficacy and 84 
chemical distribution were characterised with an array of analytical techniques. The results 85 
from this study should help to build platform to aid future work with various fabrication 86 
methods, such as extrusion and shaping using 3D printing.  87 
2. Materials & Methods 88 
2.1 Materials  89 
Polycaprolactone (PCL) with a mean molecular weight of 80 kD, Irgasan (variation of 90 
Triclosan, >97%), Levofloxacin (>98%), and all the solvents used for the electrospinning 91 




were obtained from Sigma Aldrich. The solvents consisting of chloroform (anhydrous, 92 
containing amylenes as stabilizers, >99%) and N,N-dimethylformamide (DMF, anhydrous 93 
99.8%). 94 
2.2 Preparation of PCL Solutions 95 
Different solutions with a polymer concentration of 12% (w/w) were prepared to be used 96 
within the electrospinning method ± this particular concentration was used due to its 97 
possessed suture retention and tensile strengths appropriate for hernia repair, as specified for 98 
similar electrospun scaffolds described by Ebersole et al [20]. Various PCL formulations 99 
were constructed of a total weight of 25 g per solution, which allowed for PCL (12% w/w) 100 
and a 9:1 (w/w) ratio of chloroform (CLF) to N,N-dimethylformamide (DMF). For the 101 
unloaded polymer solution, 3 g of PCL was dissolved in 22 g of CLF:DMF (9:1) which was 102 
initially mixed through 30 min in a centrifuge, a further 30 min in a sonicator (Elma S30 103 
Elmasonic) and a final 1 h with a magnetic stirrer. This process was vital to ensure that the 104 
solution was fully homogeneous. The solution was left overnight, and a further 30 min of 105 
sonication applied the following morning in order to confirm the homogeneity of the solution. 106 
For the irgasan-loaded solutions, the same method was applied, except the solution contained 107 
1% (w/w) irgasan. The concentration of the levofloxacin-loaded solutions was 0.5% (w/w), 108 
providing sufficient sensitivity in the release cell for accurate UV analysis.  All the 109 
preparations turned to clear solutions. These observations were interpreted to determine that 110 
the solutions had successfully homogenised. The solutions were then subsequently used in 111 
the electrospinning process and for rheological analysis. 112 
2.3 Electrospinning of PCL Solutions 113 
The PCL test specimens were fabricated for each polymeric solution, using a custom in-house 114 
electrospinning apparatus, which consisted of a syringe pump (Harvard Apparatus PHD 2000 115 




infusion, US) and two 30kV high-voltage power supplies (Alpha III series, Brandenburg, 116 
UK). The polymer solution was loaded into glass syringe and fed through tubing with a metal 117 
needle tip attached at the end. The needle was clamped into place, to allow a high-voltage 118 
supply to run through it, which allowed an electric field to be created between the needle and 119 
the target plate. The syringe was clamped to a pump, which determined the specific injection 120 
flow rate of the polymeric solutions. For each of the three solutions (e.g. unloaded, irgasan-121 
loaded, and levofloxacin-loaded), 3 varying flow rates of 0.5, 1 and 1.5 ml h-1 were applied 122 
across varying voltages of 2 kV ± 5 kV (needle) and 10 kV ± 18 kV (target plate). The 123 
variation in flow rate and applied voltages was to correct any problems that occurred during 124 
IDEULFDWLRQLHµVSLWWLQJ¶RIVROXWLRQat the target plate, or any potential beading (which was 125 
examined through SEM). The fabrication of this solution was electrospun onto the target that 126 
was covered with aluminium foil, in order for the final material to be removed and used for 127 
further characterisation. The final yield of electrospun PCL resulted in thin, flexible sheets of 128 
material. 129 
2.4 Rheological Studies 130 
A Thermo Scientific HAAKE MARS II rheometer with a P35 TiL cone and plate was used to 131 
measure the rheological and mechanical behaviour of the different unloaded and loaded 132 
polymeric solutions. The objective of this experiment was to examine the viscoelastic 133 
properties of the PCL solution, specifically to determine whether the irgasan or levofloxacin 134 
is having an effect on the mechanical properties of the polymer. The method used was taken 135 
and modified from the rheological study undertaken by Bubel et al [15]. In briefly, an 136 
oscillating amplitude sweep between 0.1 Pa ± 1000 Pa at a frequency of 1 Hz was used to 137 
determine the linear viscoelastic region (LVER) of the samples. Once the LVER is 138 
determined from the amplitude sweep, a downwards oscillating frequency sweep from 10 Hz 139 
± 0.1 Hz with a shear stress (Pa) within the LVER was then used in order to help understand 140 




the nature of the solutions concerning strength and stability. The experiments were repeated 4 141 
times per solution, and for each experiment, each data point (20 data points per method) was 142 
optimised to repeat each measurement 5 times. 143 
2.5 Scanning Electron Microscopy (SEM) 144 
The morphology and diameter of individual fibres spun from PCL solution were determined 145 
from scanning electron micrographs of each sample (TM-1000, Hitachi, UK, Ltd.). The 146 
samples were mounted on an aluminium plate with conductive tape. Images of fibres were 147 
taken at various locations of each electrospun PCL scaffold in order to determine the overall 148 
uniformity of fibres. Prior to imaging, the samples were sputter coated with gold for 30 sec 149 
using a Leica EM ACE200 vacuum coater, the process being repeated four times in order to 150 
increase the conductivity of the samples. 151 
2.6 Atomic Force Microscopy (AFM) 152 
Further morphological analysis was undertaken through atomic force microscopy. A 153 
Multimode 8 microscope (Bruker, USA), with Scanasyst-Air probes (Bruker, USA) was used 154 
in Peak Force Quantitative Nano Mechanics (QNM) mode, as described by Lamprou et al 155 
[21]. The imaging of the fibres was performed under ambient conditions, with a silicon 156 
cantilever probe. The tip radius of the probe and the spring constant were calculated to be in 157 
the regions of 0.964 nm (18° tip half angle) and 0.4935 N/m, respectively. The scan sizes 158 
ranged from 200 nm to 25 µm, at a scan rate of 0.977 Hz with 256-sample resolution. The 159 
Roughness Average (Ra) values were determined by entering surface scanning data, and 160 
digital levelling algorithm values were determined using Nanoscope Analysis software V1.40 161 
(Bruker USA). AFM images were collected from two different samples and at random spot 162 
surface sampling. 163 




2.7 Contact Angle Goniometry (CAG) 164 
To monitor changes in wettability of the scaffolds, sessile drop contact angle for distilled 165 
water was measured by contact angle goniometry, using a contact angle goniometer (Kruss 166 
G30, Germany) as described by Lamprou et al [22].  167 
2.8 In Vitro Drug Release Studies 168 
The drug releases of the irgasan/levofloxacin loaded PCL scaffolds were measured in order to 169 
determine the release profile of the drugs. Samples of PCL-IRG were immersed in phosphate 170 
buffered saline (PBS) containing 0.5% sodium dodecyl sulfate (SDS) at 37 °C, and samples 171 
of PCL-LEVO were immersed in PBS only at 37 °C. This release study was based on the 172 
method cited by Duan et al [23]. The solutions were agitated using a shaker at a rate of 80 173 
rev/min. The UV absorbance of both drugs was measured: irgasan at 280 nm [24], and 174 
levofloxacin at 292 nm [25] respectively. Measurements were taken at intervals at 15 min, 30 175 
min, 1 h, 2 h, 4 h, 8 h, 24 hrs and every day after the 24 h mark for up to 7 days. At each 176 
point, 4 ml of solution was taken from the vial and replaced with fresh in order to satisfy the 177 
perfect-sink conditions and keeping the volume of the solution constant. 178 
2.9 Antibacterial Studies 179 
The antibacterial efficacy of the drug loaded electrospun scaffolds were tested against 180 
Escherichia coli (E. coli) 8739 and Staphylococcus aureus (S. aureus) 29213. S. aureus is 181 
Gram positive, E. coli is Gram negative and both bacteria are common causes of nosocomial 182 
infections. . Both irgasan and levofloxacin should have antibacterial effects. For this study, an 183 
agar diffusion method was used. Luria-Bertani (LB) agar was prepared from a formulation of 184 
5 g tryptone, 2.5 g yeast extract, 5 g NaCl in 475 ml of deionized water. The LB agar was 185 
autoclaved and poured into 20ml plates. The E. coli and S. aureus were grown overnight in 5 186 




ml of LB Broth, with both bacteria inoculated from a single colony. 150 µL of the E. coli and 187 
S. aureus cultures were spread onto six different plates of LB agar. Three plates consisted of 188 
spread E. coli, including a scaffold free plate, which acted as a control ± the other 2 plates, 189 
were divided into 4 sections, with 1 section containing an unloaded PCL scaffold, and the 190 
other 3 containing PCL-irgasan and PCL-levofloxacin scaffolds. This procedure was repeated 191 
for three plates of spread S. aureus. The plates were incubated for 24 h, and subsequently 192 
examined. Diameters of the zones of growth inhibition were measured, and these data 193 
compared across the drugs and bacterial strains. This method was based on the method 194 
described by Davachi et al [26]. 195 
2.10 Time of Flight Secondary Ion Mass Spectrometry (ToF-SIMS) 196 
ToF-SIMS data was acquired using a ToF-SIMS V mass spectrometer (ION-TOF GmbH, 197 
Münster, Germany) based at the Wolfson Foundation Pharmaceutical Surfaces Laboratory at 198 
the University of Strathclyde.  The instrument is equipped with a bismuth liquid metal ion 199 
gun (LMIG), an argon gas cluster ion beam (GCIB) and a gridless reflectron time-of-flight 200 
mass analyzer.  201 
Three different acquisition modes, detailed below, were used to analyse the fibres: high mass 202 
resolution spectroscopy, depth profiling, high lateral resolution imaging. Owing to the 203 
insulative nature of the materials, a low-energy electron beam (21 V) was used to compensate 204 
for charging.  205 
2.10.1 High Mass Resolution Spectroscopy 206 
For an optimal mass resolution, the primary ion beam (Bi3++ primary ions) was pulsed at 10 207 
kHz frequency with a pulse width of 17.0 ns. The primary ion gun energy was set at 30 kV 208 
and the pulsed target current was approximately 0.63 pA. Data was collected both in the 209 




positive and in the negative secondary ion polarities, in three replicates; each acquisition was 210 
made from different areas of the samples used in this study. The analysed area and the 211 
DFTXLVLWLRQWLPHIRUHDFKUHSHWLWLRQZHUHUHVSHFWLYHO\ȝPîȝPDQGVHFRQGV212 
delivering a primary ion dose density (PIDD) of approximately 4.6 × 1012 (primary ions/cm2). 213 
Reference spectra for pure Levofloxacin and Irgasan compounds were acquired in positive 214 
and negative ion mode from 0 to 400 Da.  215 
2.10.2 High Lateral Resolution Imaging 216 
The LMIG was operated using the imaging mode, with high lateral resolution, and Bi3++ was 217 
selected as primary ion beam. The primary ion gun energy was 30 kV and the pulsed target 218 
current was approximately 0.048 pA. High lateral resolution ion images were collected over a 219 
VXUIDFHDUHDRIȝPîȝPXVLQJDSXOVHGDQDO\VLVEHDPSXOVHZLGWK QV. The 220 
UHVROXWLRQZDVîSL[HOVSHULPDJHSL[HOZLGWKZDVFLUFDȝP(DFKLPDJHZDV221 
obtained with a final ion dose of 6.5 × 1012 primary ions/cm2 or less. The dose was kept 222 
below the static limit of 1013 primary ions/cm2 to minimize surface damages during the 223 
analysis. The images were processed with the ION-TOF SurfaceLab 6.6 software (Münster, 224 
Germany). 225 
2.10.3 3D Imaging 226 
The LMIG and the GCIB were employed in a dual-beam configuration to collect the depth 227 
profile and the 3D image data. The LMIG was operated in pulsed mode to investigate the 228 
lateral distribution of chemical species, while the Argon source was operated in DC mode to 229 
remove multiple layers of material from the sample surface between the analytical cycles. For 230 
the depth profiling analysis, the dual beam experiment used a 30 kV Bi3++ primary ion beam 231 
for analysis and a 10 kV Ar1500+ beam for sputtering. The pulsed current of the Bi3++ primary 232 
ion beam was 0.048 pA and the DC current of the cluster Ar1500+ was 10.22 nA, with a 500 233 




seconds analysis time and 4 seconds sputtering time. The raster areas of the pulsed analysis 234 
EHDPVDQGWKH'&VSXWWHUZHUHȝPîȝPDQGȝPîȝPUHVSHFWLYHO\7KH235 
resolution was 256 × 256 pixels per image SL[HOZLGWKRIDERXWȝPData was collected 236 
in the negative secondary ion mode. In the course of each acquisition, mass spectral 237 
information at each image pixel was collected in the m/z range of 0-917 m/z.  238 
2.11 Statistical Analysis  239 
All experiments were performed in triplicate with calculation of means and standard 240 
deviations. Two-way analysis of variance (ANOVA) was used for multiple comparisons 241 
DORQJ ZLWK 7XNH\¶V PXOWLSOH FRPSDULQJ tests, followed by T-test to access statistical 242 
significance for paired comparisons. Significance was acknowledged for p values lower than 243 
0.05.  244 
3. Results and discussion 245 
3.1 Rheological Studies 246 
For each polymeric solution, multiple amplitude sweeps were used in order to correctly 247 
identify the linear viscoelastic region (LVR). This was repeated to detect any major variations 248 
in the LVR, and for a more accurate shear stress to be used in the frequency sweeps. For each 249 
RI WKH VDPSOHV HODVWLF PRGXOXV *¶ YLVFRXV PRGXOXV *¶¶ DQG VKHDU YLVFRVLW\ Ș ZDV250 
calculated and subsequently analysed.  251 
It can be seen in figure 1 that for all three solutions, the viscosity modulus (from 30 Pa to 80 252 
Pa) is considerably greater than the elastic modulus (0.5 Pa to 6 Pa) which implies that the 253 
solutions exhibit significantly less elastic properties. As observed in figure 1c, both polymer-254 
drug-loaded solutions of irgasan and levofloxacin show differences in the VKHDUYLVFRVLW\Ș). 255 
The amplitude sweep demonstrated that these drugs caused a reduction in all three of these 256 




parameters ± this may be caused by the possible transition from semi-dilute to dilute regime, 257 
where there are less polymer chain entanglements [27]. It is also worth noting that the LVR 258 
for the drug-loaded solutions was extended; the unloaded PCL solution had a short LVR of 259 
between 50 Pa to 100 Pa (shear stress), which then resulted in shear thinning at high shear 260 
stresses. These long LVRs are indicative of well-dispersed, stable polymer-drug systems. 261 
This behaviour of Newtonian to shear thinning has been previously observed in other studies; 262 
it can be attributed to the formation of physical bonding between the drug and the polymer, 263 
which causes an increase in the solution viscosity [28].  264 
The frequency sweep data shown in figure 2 are indicative of how the drug dispersed in the 265 
matrix affected the overall structure. Again, it was observed that loading the polymer solution 266 
with drugs had an effect, with measured viscosity in all three samples appearing to be 267 
frequency dependent.  According WRGDWDLQERWK*¶DQG*¶¶JUDSKV*¶¶was shown to be the 268 
dominating effect *¶ UDQJLQJ IURP seven WR3D DQG*¶¶ UDQJLQJ IURP WR3D 269 
Long regions of viscoelasticity normally imply that there is a certain degree of stability 270 
within the polymer matrix; however, the frequency sweep implies otherwise. It appears that 271 
*¶ DQG *¶¶ DUH ERWK IUHTXHQF\ GHSHQGHQW ZKLFK LPSOLHV WKDW WKH V\VWHP KDV OLWWOH LQWHUQDO272 
network and is easily disturbed [15]. 273 
3.2 Fibre Morphology 274 
Figure 3 shows SEM images of the various unloaded and drug-loaded PCL scaffolds. Smooth 275 
morphology can be observed in all 3 different scaffolds and at a 12% concentration of 276 
polymer, there is no significant beading or any visible signs of either API outside of the 277 
fibres. The major differences across the three different scaffolds are the fibre size ± the 278 
addition of irgasan reduced the average fibre diameter to 1.623 ± 1.9 µm. These fibres appear 279 
to be relatively consistent in size compared to other various PCL-fibre studies, 1.1 ± 6.6 µm, 280 




2.7 ± 2.0 µm and 1.83 ± 0.050 µm [9], [29], [30]. The morphology of the levofloxacin-loaded 281 
fibres appeared to differ from the unloaded and irgasan loaded fibres: whilst there appears to 282 
be a smooth morphology, the fibres appear more densely packed with a greater µFXUYDWXUH¶RI283 
the fibres. These fibres are also greater in diameter in comparison with the PCL-IRG scaffold, 284 
with an average fibre diameter or 2.865 ± 3.0 µm. The PCL-LEVO fibres appear to be much 285 
larger in diameter compared with studies by Jalvandi et al [12] (600 ± 800 nm), Puppi et al 286 
[31] (219.2 ± 55.1 nm) and Park et al [32] (232 ± 20.4 nm). This variation in fibre diameter 287 
could possibly be attributed to the higher voltage applied to the target plate during the 288 
electrospinning process ± for PCL and PCL-IRG solutions, the voltage applied varied 289 
between 10 ± 12 kV whereas the PCL-LEVO solution was ± 18 kV. There is a critical value 290 
of applied voltage, and the increase in the diameter with an increase in the applied voltage are 291 
attributed to the decrease in the size of the Taylor cone and increase in the jet velocity for the 292 
same flow rate [33]. 293 
Considering the morphology of the fibres at a greater detail and image resolution, the AFM 294 
characterisation showed a significant difference between the irgasan-loaded and levofloxacin-295 
loaded fibres. Figure 4a shows the smooth morphology of the PCL-IRG scaffold at a 400 nm 296 
scale, and it can be clearly seen that there appears to be no signs of API on the surface of the 297 
polymer. This suggests that the irgasan is integrated into the polymeric matrix. In contrast, it 298 
was found using AFM that within certain areas of the PCL-LEVO scaffold, there appeared to 299 
be regions with crystalline API sitting at the surface (figure 4b).  300 
3.3 Surface Characterisation 301 
The CAG results for the irgasan-loaded fibres indicated an increase in the hydrophobicity of 302 
the scaffold in comparison to the unloaded PCL scaffold ± the water drop took 45 minutes to 303 
absorb fully into the PCL-IRG scaffold, and this slow nature of absorption potentially 304 




indicates that the irgasan may release in a sustained mechanism. This is most likely due to the 305 
hydrophobic nature of irgasan combined within the polymeric matrix of PCL, which also has 306 
a certain degree of hydrophobicity. The CAG results for the levofloxacin-loaded scaffolds 307 
were inconclusive given that hydrophilic nature of levofloxacin- the water droplet applied 308 
was absorbed almost immediately; therefore, no data could be obtained. However, this does 309 
support the hypothesis that there may be an amount of levofloxacin sitting at the surface of 310 
the sample ± the quick absorbance of the water droplet may be the levofloxacin uptake. 311 
3.4 Drug Efficacy of Electrospun Scaffolds 312 
The release of irgasan (figure 5) from the PCL-irgasan scaffold appeared to exhibit sustained 313 
release behaviour of the encapsulated drug. The final cumulative drug release was found to 314 
be at 50 %; although more irgasan will be released beyond 200 h (equilibrium had not been 315 
observed at the 200 hr). The behaviour of the PCL-levofloxacin scaffold was entirely 316 
different to the irgasan-loaded scaffold. It exhibited burst release behaviour and the antibiotic 317 
was almost entirely lost from the matrix within the first 15 min of measurements.. The final 318 
cumulative drug release was also found to be at 50 %. This burst release behaviour is 319 
consistent with the manner in which the drug is associated with the polymer matrix ± the 320 
previous SEM and AFM were indicative of the presence of levofloxacin on the surface of the 321 
fibres in some areas. 322 
Determining the drug release profiles of the drugs was a crucial part of this study, as 323 
divergent behaviours helped us to characterise bridging properties indicating the manner in 324 
which irgasan and levofloxacin dispersed within the polymer matrix. The irgasan released 325 
steadily over 145 hours, which would suggest that the drug is being released through 326 
molecular diffusion [34]. The levofloxacin exhibited a burst release mechanism, although this 327 




may be attributed to the mechanism in which levofloxacin functions in most polymers [32], 328 
due to the way the drug is adsorbed on to the surface of the polymer [31], [35]. 329 
The main factors that could be expected to influence the drug release kinetics in this study 330 
can be summarised as follows are: 331 
x Material matrix: this includes the composition, structure and degradation of polymer; 332 
however, the polymer showed no signs of degradation and is known to show a high 333 
degree of stability. 334 
x Release medium: the irgasan was released in a buffer of PBS and sodium dodecyl 335 
sulphate (surfactant), therefore it could be suggested either that the surfactant is 336 
interacting with the polymer/drug or that it is changing the ionic strength of the buffer 337 
[36]. 338 
x Drug compounds: Fu and Kao [34] cite solubility, stability charges and interaction 339 
with matrix as major factors with the drug that may affect the drug release kinetics. 340 
The results in our studies can demonstrate this, given that potential charges of the 341 
drug were affecting fabrication, therefore it can be assumed that the charges of irgasan 342 
and levofloxacin may be affecting the drug release kinetics.  343 
3.5 In-Vitro Antibacterial Activity 344 
The antibacterial efficacy (Figure 6) of both irgasan and levofloxacin-loaded scaffolds were 345 
tested against strains of E. coli and S. aureus, with the efficacy specifically determined by 346 
visual zones of inhibition on the agar plate. The PCL-irgasan scaffold showed signs of some 347 
activity, albeit weak, against E. coli with an average inhibition zone diameter of 0.7 ± 0.5 cm. 348 
However, the irgasan-loaded scaffold was particularly successful inhibiting the growth of S. 349 
aureus with an average inhibition zone diameter of 1.8 ± 0.5 cm. There was a higher-level 350 
efficacy observed within the PCL-levofloxacin cultures of both E. coli and S. aureus. Both 351 




strains of bacteria were inhibited on the agar plate with an average diameter of no growth of 352 
2.6 cm. The antibacterial studies have shown that there is a high efficacy of bacteria 353 
inhibition in both irgasan and levofloxacin-loaded scaffolds across E. coli and S. aureus 354 
bacteria. The levofloxacin-loaded scaffolds demonstrated larger values of inhibition zones, 355 
for both bacteria ± this should be the case, given that levofloxacin is a broad-spectrum 356 
antibiotic, active against both gram positive and gram negative. The irgasan-loaded scaffold 357 
showed stronger inhibition to the S. aureus bacteria; however, this should not be viewed as a 358 
negative result. S. aureus is a gram-positive bacterium that is commonly found on the skin, 359 
therefore is a major cause of nosocomial wound infection [37]. The hydrophobic natures of 360 
irgasan and PCL, and potential stronger interactions between drug and polymer are likely to 361 
aid the sustained release from the fibres ± this sustained release can be observed in the 362 
previous in vitro drug release study, and observed in the reduced inhibition of E. Coli [9]. 363 
3.6 ToF-SIMS Analysis 364 
Imaging and 3D imaging techniques showed a difference in the distribution of the active 365 
pharmaceutical ingredients (API) between Irgasan-loaded and Levofloxacin-loaded fibres. 366 
PCL is identified by the ion at m/z 113 ([C6H9O2] - [M-H]-), Levofloxacin by the ions at m/z 367 
360 ([C18H19FN3O4] - [M-H]-) and m/z 316 ([C17H19FN3O2] -), and Irgasan by the ions at m/z 368 
287 ([C12H635Cl3O2] - [M-H]-), m/z 289 ([C12H635Cl237Cl1O2] -) and m/z 291 369 
([C12H635Cl137Cl2O2] -). The total ion images and the overlays of single ion images for the 370 
characteristic peaks of PCL (grey) and the two drugs (yellow) are reported in Figure 7. The 371 
ion images show a homogeneous distribution of Irgasan, throughout the electrospun fibres, 372 
whilst the Levofloxacin appears to be concentrated in several small areas. This was 373 
confirmed by 3D imaging, where Irgasan characteristic peaks appeared to be homogeneously 374 
distributed in the volume (Figure 8a). Conversely, Levofloxacin had an intense signal 375 
localized to small areas and mainly on the surface (Figure 8b). 376 




4. Conclusions 377 
The purpose of this study was to fabricate drug-loaded fibres that may potentially be used 378 
within a hernia repair context. The good understanding of the relationship between the 379 
solution viscosity and the spinning parameters is essential if the technique is to be effective, 380 
hence the need to characterise the effect of drug loading on the rheological behaviour of the 381 
spinning solutions. It was observed that the addition of both irgasan and levofloxacin had a 382 
direct influence on the rheological behaviour of the solutions; a reduction in elastic modulus, 383 
viscous modulus, and shear viscosity occurred, which may cause a reduction in polymer 384 
chain entanglements. However, this explanation may not be the only viable one ± rheological 385 
behaviour of drug-loaded solutions has been widely researched, although further 386 
characterisation into the molecular interactions between drug and polymer may give further 387 
insight into why the solution behaviour changes significantly. Atomic force microscopy 388 
indicated that crystals, probably of levofloxacin were present on the surface of the polymer 389 
fibres, and this was crucial in explaining the behaviour of the drug during in vivo release 390 
studies and antibacterial activity profile. The presence of levofloxacin at the surface of the 391 
polymer was confirmed through contact angle goniometry (immediate absorbance of the 392 
water droplet showed the hydrophilic nature of levofloxacin in action), in vitro release studies 393 
(the drug demonstrated a burst release behaviour), antibacterial studies (an increased average 394 
inhibition zone repelled both bacteria types immediately) and ToF-SIMS.  In the ToF-SIMS 395 
study, the molecular weight of levofloxacin was shown at various areas across the fibres and 396 
the 3D imaging of the matrix indicated there was a certain degree of drug encapsulation. This 397 
study has contrasted the incorporation of two different drugs within an electrospun fibre, and 398 
shown that through bridging chemical, mechanical and biological studies, their behaviours 399 
can be fully interpreted.  The next stages of this research are to now assess whether these 400 




constructs are useful within any clinical scenario, and in particular, within the treatment of 401 
hernia repair.  402 
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Figure Captions 537 
Figure 1 a: Amplitude sweep viscous modulus (G¶GDWDIRU3&/3&/-IRG and PCL-LEVO 538 
solutions; b: $PSOLWXGH VZHHS YLVFRXV PRGXOXV *¶¶ GDWD IRU 3&/ 3&/-IRG and PCL-539 
LEVO solutions; c$PSOLWXGHVZHHSVKHDUYLVFRVLW\Ș) data for PCL, PCL-IRG and PCL-540 
LEVO solutions. 541 
Figure 2 a: )UHTXHQF\VZHHSHODVWLFPRGXOXV*¶GDWDIRU3&/ PCL-IRG and PCL-LEVO 542 
solutions; b )UHTXHQF\ VZHHS YLVFRXV PRGXOXV *¶¶ GDWD IRU 3&/ PCL-IRG and PCL-543 
LEVO solutions; c:  )UHTXHQF\VZHHSVKHDUYLVFRVLW\ȘGDWDIRU3&/3&/-IRG and PCL-544 
LEVO solutions. 545 
Figure 3: SEM images of PCL (a), PCL-IRG (b) and PCL-LEVO (c) electrospun fibres. 546 
Figure 4 a: AFM image of PCL-IRG fibres; b: AFM image of PCL-LEVO fibres. 547 
Figure 5: Cumulative drug release percentages for the release of IRG and LEVO in PBS 548 
media. 549 
Figure 6: Images showing the average zone of inhibition of PCL-IRG and PCL-LEVO 550 
against bacterial strains of E. coli and S. aureus. 551 
Figure 7a/b: The images above are acquired with a high lateral resolution mode, which 552 
enables to easily visualise the nanofibers (total ion image A and B) and the distribution of the 553 
API (colour overlay images C and D); c: Overlay of [C6H9O2] - (PCL) in grey and 554 
[C12H6Cl3O2] - (Irgasan) in yellow; d: Overlay of [C6H9O2] - (PCL) in grey and of 555 
[C17H19FN3O2] - and [C18H19FN3O4] - (Levofloxacin) in yellow.  556 
Figure 8a: The 2D (left) and 3D images show the distribution of [C6H9O2] - (PCL) in grey 557 
and [C12H6Cl3O2] - ,UJDVDQLQ\HOORZ7KHDQDO\VHGYROXPHLVȝP[ȝPRQWKH;-Y 558 





visualization.  560 
Figure 8b: The 2D (left) and 3D images show the distribution of [C6H9O2] - (PCL) in grey 561 
and of [C17H19FN3O2] - and [C18H19FN3O4] - (Levofloxacin) in yellow. The analysed volume is 562 
ȝP[ȝPRQWKH;-<D[HVDQGaȝPRQWKH=D[LV$YLHZHGIURPWKHWRSDQG563 
(B) inclined in order to aid 3D visualization.  564 
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